Six days after a senior FDA official sent a sweeping internal email claiming that COVID vaccines had caused the deaths of "at ...

A strict new vaccine approval process in the U.S. could dramatically slow things down for biopharma and the public, experts ...

The FDA has been rumored to be evaluating whether or not to place a black box warning on vaccines for COVID-19.

After a senior Food and Drug Administration official sent an internal email claiming that Covid vaccines had caused the deaths of “at least 10 children,” 12 former FDA commissioners released an ...

The award is in response to an “unsolicited proposal,” according to documents in the Federal Register. The University of ...

Biostatistician Jeffrey Morris discusses his analysis of the vaccine monitoring system — and how it could be improved.

The US Department of Health and Human Services is planning to overhaul the schedule of recommended vaccines for children in ...

The agency’s high-level turnover and conflicting policy decisions on drug oversight have fueled concerns about the leadership ...

After patient deaths from interstitial lung disease in a lung cancer trial testing the antibody-drug conjugate ifinatamab deruxtecan, the FDA placed a partial hold on Daiichi Sankyo and Merck's global ...

The Trump administration has announced sweeping policies that, if enacted, could effectively end gender-affirming care for ...

A monkeypox vaccine or antibody therapy may have taken a step closer to reality, as AI reveals new drug target.

As 2025 closes, biopharma and healthcare are learning to live on shifting ground. | Fierce reporters break down the forces that shaped biopharma and healthcare in 2025 and what lies ahead in 2026.